問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Linkou Chang Gung Medical Foundation
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
Division of Thoracic Medicine
下載
2011-12-07 - 2014-06-30
Condition/Disease
Test Drug
Participate Sites6Sites
Terminated6Sites
2011-09-01 - 2013-09-01
Participate Sites8Sites
Terminated8Sites
2010-02-01 - 2011-01-31
Participate Sites13Sites
Terminated13Sites
2015-11-01 - 2017-10-31
Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations
ASP8273
Participate Sites9Sites
Terminated9Sites
Division of Hematology & Oncology
2011-07-01 - 2016-03-31
Participate Sites7Sites
Terminated7Sites
2017-05-01 - 2023-10-30
NSCLC
Nivolumab (BMS-936558),Ipilimumab (BMS-734016)
Participate Sites16Sites
Terminated14Sites
2020-06-12 - 2022-09-01
Candidemia and/or Invasive Candidiasis
Rezafungin
Participate Sites5Sites
Not yet recruiting4Sites
Terminated1Sites
2012-07-01 - 2015-06-30
2014-06-30 - 2017-06-30
COPD
Mepolizumab
Terminated4Sites
Study ended1Sites
Division of General Internal Medicine
2012-07-01 - 2019-08-31
A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis
Isoniazid tablet formulated with excipient HUEXC030
全部
